(Q54740050)

3 June 2018

title

Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients. (English)

1 reference

3 June 2018

1 reference

Lin Wang

1

1 reference

3 June 2018

Xiaobei Wang

series ordinal

2

1 reference

3 June 2018

Xiu Nie

series ordinal

3

1 reference

3 June 2018

Ling Ma

series ordinal

4

1 reference

3 June 2018

publication date

10 June 2009

1 reference

3 June 2018

Journal of Huazhong University of Science and Technology [Medical Sciences]

published in

1 reference

3 June 2018

volume

29

1 reference

3 June 2018

issue

3

1 reference

3 June 2018

page(s)

354-358

1 reference

3 June 2018

Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?

cites work

1 reference

12 December 2020

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis

1 reference

12 December 2020

Breast cancer subtypes and survival in patients with brain metastases

1 reference

12 December 2020

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

12 December 2020

Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic va

1 reference

12 December 2020

Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals

1 reference

12 December 2020

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

1 reference

12 December 2020

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.

1 reference

12 December 2020

Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice

1 reference

12 December 2020

HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring

1 reference

12 December 2020

Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR

1 reference

12 December 2020

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

1 reference

12 December 2020

10.1007/S11596-009-0318-7

Identifiers

DOI

1 reference

3 June 2018

1 reference

3 June 2018